V. Pyko et al. suggested that GSK-3β inhibition enhances the antineoplastic effect of TMZ on T98G, U138, U251, and U87 human glioma cells by decreasing the expression of MGMT via its c-myc-mediated promoter methylation [119]. The gene discussed is GSK3B; the disease is glioma.